Dual-component tablets with DPP-4 inhibitor vildagliptin and metformin hydrochloride targeting hyperglycemia in type 2 diabetes. Pharmaceutical suppliers provide to institutional buyers like government health programs and private clinics, enabling distribution to diabetologists for routine patient management.